Table 3 Characteristics of patients classified according to presence or absence of severe adverse drug events after enoxaparin administration

Case, no. (%)

108 (84.4)

20 (15.6)

-

Age (years)^a

77.7 ± 5.00

76.5 ± 5.26

0.34

 male

23 (21.3)

5 (25.0)

0.77

 female

85 (78.7)

15 (75.0)

Height (cm)^b

150 (138–175)

146 (135–176)

0.67

Body weight (kg)^b

58 (38–85)

53.5 (39–91)

0.31

 2000 mg/day

41 (38.0)

4 (20.0)

0.14

 4000 mg/day

67 (62.0)

16 (80.0)

 yes

5 (4.63)

2 (10.0)

0.30

 yes

42 (38.9)

8 (40.0)

1.00

Operative time, (min)^b

107 (65–260)

117.5 (85–230)

0.03

Volume of bleeding during surgery (mL)^b

90 (0–1530)

115 (0–420)

0.83

 Total serum protein (g/dL)^a

6.03 ± 0.59

5.46 ± 0.57

<0.01

 Serum creatinine (mg/dL)^b

0.67 (0.35–2.13)

0.67 (0.46–1.08)

0.88

 BUN (mg/dL)^b

12.9 (7.4–23.3)

12.65 (9.2–24.3)

0.76

 AST (IU/L)^b

20.0 (11.0–52.0)

18.5 (11.0–80.0)

0.25

 ALT (IU/L)^b

13.0 (5.0–57.0)

12.0 (6.0–50.0)

0.39

 LDH (IU/L)^b

204.5 (131–390)

172 (122–250)

<0.01

 ALP (IU/L)^b

185 (94–337)

188 (107–398)

0.86

 γ-GTP (IU/L)^b

14 (8–143)

11.5 (7–460)

0.23

 ChE (IU/L)^b

229 (128–392)

205 (108–401)

0.09

 Total bilirubin (mg/dL)^b

0.9 (0.3–2.7)

0.8 (0.4–2.0)

0.18

 WBC (10³/μL)^b

85.5 (45–405)

94 (58–140)

0.35

 Hb (g/dL)^a

11.0 ± 1.17

9.75 ± 1.21

<0.01

 Platelet (10⁴/μL)^a

18.3 ± 5.52

17.3 ± 6.75

0.56

 CRP (mg/dL)^b

4.56 (1.04–14.04)

5.425 (2.29–8.42)

0.20

 Hypertension

79 (73.2)

12 (60.0)

0.28

 Diabetes

14 (13.0)

1 (5.0)

0.46

 Dyslipidemia

33 (30.6)

3 (15.0)

0.19

 Chronic heart failure

4 (3.70)

2 (10.0)

0.24

 Cerebral vascular disease

5 (4.63)

1 (5.0)

1.00

 NSAIDs

102 (94.4)

19 (95.0)

1.00

 Low dose aspirin

13 (12.0)

1 (5.0)

0.70

 Clopidogrel

3 (2.78)

0 (0.0)

1.00

 Ticlopidine

2 (1.85)

0 (0.0)

1.00

 Cilostazol

2 (1.85)

0 (0.0)

1.00

 Limaprost alfadex

7 (6.48)

1 (5.0)

1.00

 Warfarin

7 (6.48)

0 (0.0)

0.60

 Raloxifene

5 (4.63)

1 (5.0)

1.00